Nature5 年
2 Synflorix™: What Have We Learned From Immunogenicity Studies?
Synflorix™ (10-valent pneumococcal conjugate vaccine; GlaxoSmithKline Biologicals ... following priming was observed between continents. 2,3 In European studies, Synflorix™ was proven to ...
GlobalData on MSN13 天
Vaxcyte enters final stage of Phase II pneumococcal vaccine trial in infants
Vaxcyte has advanced to the Phase II trial’s second and final stage (Stage 2) assessing its 31-valent pneumococcal conjugate ...
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the ...
Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data -- -- Company Expects to Announce VAX-31 Infant Study Topline Safety, Tolerability and Immunogenicity ...
来自MSN15 天
MRK Gets Positive CHMP Nod for 21-Valent Pneumococcal Jab Capvaxive
In the past year, shares of Merck have plunged 21.7% compared with the industry’s decrease of 2.6%. Image Source ... to PCV20 (pneumococcal 20-valent conjugate vaccine) in adults aged 18 ...
Vaxcyte advances second stage of Phase 2 study evaluating VAX-31
Vaxcyte (PCVX) announced that the first study participants have been dosed in the second and final stage of the ongoing Phase 2 study of VAX-31 ...